Pancreatic cancer

Through EPIC we are involved in the "PanScan" initiative, which has performed the first GWAS on pancreatic cancer, and is continuously being expanded to additional samples of cases and controls. In parallel, we have set up the PANcreatic Disease ReseArch (PANDoRA) consortium (http://pandoraconsortium.wixsite.com/pandora), an international initiative to collect DNA samples of pancreatic cancer cases and controls, in order to perform studies on polymorphisms and pancreatic cancer risk (we currently have samples of over 4,000 cases and about 5,000 controls). In addition, the availability of survival data for a subset of cases allows us to study whether SNPs involved in pancreatic cancer risk are relevant also as prognostic factors. In collaboration with the National Cancer Institute of the USA and other consortia, we will perform a genome-wide association study (GWAS) on pancreatic cancer risk and prognosis. We are also collecting samples of cases of other pancreatic diseases, including chronic pancreatitis, which is one of the strongest risk factors for pancreatic cancer, pancreatic neuroendocrine tumors (PNET) and preneoplastic pancreatic lesions such as intra-pancreatic mucinous neoplasms (IPMN).

to top